Results 161 to 170 of about 964,883 (379)
A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival
Molecular Oncology, EarlyView.There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas +20 morewiley +1 more sourceEscape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells
Molecular Oncology, EarlyView.Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting Minenur Kalyoncu, Dilara Demirci, Sude Eris, Bengisu Dayanc, Ece Cakiroglu, Merve Basol, Merve Uysal, Gulcin Cakan‐Akdogan, Fang Liu, Mehmet Ozturk, Gökhan Karakülah, Serif Senturk +11 morewiley +1 more sourceSpeech Communication [PDF]
Contains reports on five research projects.C.J. Lebel FellowshipNational Institutes of Health (Grant 5 T32 NSO7040)National Institutes of Health (Grant 5 R01 NS04332)National Institutes of Health (Grant 5 R01 NS21183)National Institutes of Health (Grant ...Abramson, Katie, Allen, Jonathan, Alwan, Abeer A., Anderson, M., Bateman, Nicholas P. T., Bickley, Corine A., Blush, M., Boyce, Suzanne E., Chapin Ringo, Carol, Chasaide, A. ni, Cohen, M., Daly, Nancy, Dubois, S., Espy-Wilson, Carol Y., Forestell, Ann F., Glass, James R., Glicksman, Laura B., Goldhor, R., Gosy, M., Halle, Morris, Hillman, Robert E., Hirahara, T., Hirose, K., Holmberg, Eva B., Hopkins, G., Howitt, Andrew William, Huang, Caroline B., Isaacs, Katy, Jankowski, Charles, Kassel, Rob, Kaufman, D. H., Kawasaki, Haruko, Key, K. K., Keyser, Samuel J., Klatt, Dennis H., Kline, K., Lamel, Lori, Landry, Joseph, Lane, Harlan L., Larkey, Leah S., Lauritzen, N., Leung, Hong, Lim, A., Locke, John L., Makhoul, J. I., Manuel, Sharon Y., Marcus, J. N., McCandless, Michael K., Mitra, H., North, Keith, Pao, Christine, Pastel, L., Perkell, Joseph S., Phillips, M., Pitrelli, John, Randolph, Mark A., Seneff, Stephanie, Shattuck-Hufnagel, Stephanie, Shaw, A., Stevens, Kenneth N., Suzuki, Noriko, Tierney, S., Volaitis, L., Webster, Jane W., Wheeler, L., Whitney, Dave, Wilson, T., Wint, Arlene E., Wong, Albert K., Wong, D., Yoshida, K., Zue, Victor W. +71 morecore ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling
Molecular Oncology, EarlyView.We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones +11 morewiley +1 more sourceAn Evaluation of the Fungistatic Activity of Serum121From the Division of Dermatology, Department of Medicine and Department of Bacteriology, University of Miami School of Medicine, Miami and Coral Gables, Florida.2This work was supported in part by a grant from the National Institutes of Health, P.H.S. No. E-1546, and in part by U.S. Army Contract #DA-49-007-MD-731.
, 1959 Frank J. Roth, Carolyn C. Boyd, Seichiro Sagami, Harvey Blank +3 moreopenalex +1 more sourceTargeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model
Molecular Oncology, EarlyView.Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker +19 morewiley +1 more sourceEvaluation of Arginase Activity in Normal Epidermal Tissue and Pathological Stratum Corneum11From the Dermatology Service, General Medicine Branch, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Maryland.
, 1958 Simon Rothberg, Eugene J. Van Scott, S.L. Newberry +2 moreopenalex +1 more source